Articles & guides — page 2
92 cited, vendor-independent pieces on the questions people actually ask — reconstitution and handling, half-lives, compound comparisons, and how to track a protocol. Research and education only; never dosing advice, never sourcing.
92 articles
BPC-157 vs TB-500 compared
BPC-157 and TB-500 side by side with the literature: two unrelated peptides, two different repair mechanisms, and two different evidence bases — explained in plain English.
PreclinicalComparisons2 minCJC-1295 vs ipamorelin compared
CJC-1295 and ipamorelin side by side in plain English: two different levers on the growth-hormone system, why they are paired, their very different half-lives, and how strong the evidence really is.
PreclinicalComparisons2 minSermorelin vs CJC-1295 vs ipamorelin
Three growth-hormone research peptides compared in plain English: two GHRH analogs (sermorelin, CJC-1295) versus a ghrelin-receptor agonist (ipamorelin), with mechanisms, half-lives, and honest evidence.
PreclinicalComparisons2 minSemaglutide vs tirzepatide compared
Semaglutide and tirzepatide side by side in plain English: one receptor versus two, their landmark trial results (STEP 1 vs SURMOUNT-1), and what a fair comparison can and can’t say.
Approved medicineComparisons2 minTestosterone cypionate vs enanthate
Testosterone cypionate and enanthate compared plainly: same hormone, two nearly identical esters differing by one carbon, and why the practical half-life difference is small.
Approved medicineComparisons2 minCJC-1295 DAC vs no-DAC
CJC-1295 with DAC versus without (mod GRF 1-29): how one small chemical anchor stretches the half-life from minutes to days, backed by the 2006 human pharmacokinetic trial.
Human clinical dataComparisons2 minOzempic vs Wegovy vs Mounjaro vs Zepbound: what is the difference?
Four famous brand names, only two actual medicines: how Ozempic/Wegovy (semaglutide) and Mounjaro/Zepbound (tirzepatide) map to two molecules and different approvals, explained clearly.
Approved medicineComparisons3 minRetatrutide vs tirzepatide compared
Retatrutide and tirzepatide compared: the step from two receptors (GIP/GLP-1) to three (adding glucagon), and what retatrutide’s 2023 phase-2 obesity trial actually showed — up to ~24% weight loss.
Human clinical dataComparisons3 minIpamorelin vs GHRP-6 vs GHRP-2
Three ghrelin-receptor (GHS) peptides compared in plain English: same class, same lever, but different "cleanliness" — why ipamorelin is called selective and GHRP-6/GHRP-2 carry side-signals.
PreclinicalComparisons2 minTesamorelin vs CJC-1295
Two GHRH-analog peptides compared: tesamorelin and CJC-1295 pull the same lever, but one is an FDA-approved medicine with trial data and the other is a research compound. That gap is the real story.
Human clinical dataHalf-life & pharmacology3 minWhat is a half-life and why does it matter?
Half-life explained plainly: what it measures, the five-half-lives clearance rule, and why it decides how often a compound is dosed. Education only.
Concept / methodHalf-life & pharmacology2 minWhat is steady-state and drug accumulation?
Steady-state explained: how repeated doses accumulate until intake balances clearance, why it takes about five half-lives to reach, and what it means for level curves.
Concept / methodZyra Labs is a research and educational utility. Nothing on this page is medical advice, a dosing recommendation, or an endorsement of any compound. We never sell or source compounds and refuse sourcing questions. Consult a qualified clinician for decisions about your health.